This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sonveaux, P. Articles by Feron, O. Search for Related Content PubMed PubMed Citation Articles by Sonveaux, P. Articles by Feron, O.

Endothelin-1 Is a Critical Mediator of Myogenic Tone in Tumor Arterioles

Implications for Cancer Treatment

¹ University of Louvain Medical School, Unit of Pharmacology and Therapeutics (FATH 5349); ² Cardiovascular Pathology Unit; ³ Biomedical Magnetic Resonance Unit and Medicinal Chemistry and Radiopharmacy Unit; and ⁴ Radiobiology and Radioprotection Unit, Brussels, Belgium

Although derived from the host tissue, the tumor vasculature is under the influence of the tumor microenvironment and needs to adapt to the resistance to blood flow inherent to the dynamics of tumor growth. Such vascular remodeling can offer selective targets to pharmacologically modulate tumor perfusion and thereby improve the efficacy of conventional anticancer treatments. Radiotherapy and chemotherapy can, indeed, take advantage of a better tumor oxygenation and drug delivery, respectively, both partly dependent on the tumor blood supply.

Here, we showed that isolated tumor arterioles mounted in a pressure myograph have the ability, contrary to size-matched healthy arterioles, to contract in response to a transluminal pressure increase. This myogenic tone was exquisitely dependent on the endothelin-1 pathway because it was completely abolished by the selective endothelin receptor A (ET_A) antagonist BQ123. This selectivity was additionally supported by the large increase in endothelin-1 abundance in tumors and the higher density of the ET_A receptors in tumor vessels. We also documented by using laser Doppler microprobes and imaging that administration of the ET_A antagonist led to a significant increase in tumor blood flow, whereas the perfusion in control healthy tissue was not altered. Finally, we provided evidence that acute administration of the ET_A antagonist could significantly stimulate tumor oxygenation, as determined by electron paramagnetic resonance oximetry, and increase the efficacy of low-dose, clinically relevant fractionated radiotherapy.

Thus, blocking the tumor-selective increase in the vascular endothelin-1/ET_A pathway led us to unravel an important reserve of vasorelaxation that can be exploited to selectively increase tumor response to radiotherapy.

This article has been cited by other articles:

				L. A. Martinez-Lemus, M. A. Hill, and G. A. Meininger The Plastic Nature of the Vascular Wall: Reply to Lee, Sandow, and DeMay Physiology, October 1, 2009; 24(5): 273 - 275. [Full Text] [PDF]

				F. Frerart, I. Lobysheva, B. Gallez, C. Dessy, and O. Feron Vascular Caveolin Deficiency Supports the Angiogenic Effects of Nitrite, a Major End Product of Nitric Oxide Metabolism in Tumors Mol. Cancer Res., July 1, 2009; 7(7): 1056 - 1063. [Abstract] [Full Text] [PDF]

				F. Frerart, P. Sonveaux, G. Rath, A. Smoos, A. Meqor, N. Charlier, B. F. Jordan, J. Saliez, A. Noel, C. Dessy, et al. The Acidic Tumor Microenvironment Promotes the Reconversion of Nitrite into Nitric Oxide: Towards a New and Safe Radiosensitizing Strategy Clin. Cancer Res., May 1, 2008; 14(9): 2768 - 2774. [Abstract] [Full Text] [PDF]

				J. DeWever, F. Frerart, C. Bouzin, C. Baudelet, R. Ansiaux, P. Sonveaux, B. Gallez, C. Dessy, and O. Feron Caveolin-1 Is Critical for the Maturation of Tumor Blood Vessels through the Regulation of Both Endothelial Tube Formation and Mural Cell Recruitment Am. J. Pathol., November 1, 2007; 171(5): 1619 - 1628. [Abstract] [Full Text] [PDF]

				H. A. Lee, E. B. Baek, K. S. Park, H. J. Jung, J. I. Kim, S. J. Kim, and Y. E Earm Mechanosensitive nonselective cation channel facilitation by endothelin-1 is regulated by protein kinase C in arterial myocytes Cardiovasc Res, November 1, 2007; 76(2): 224 - 235. [Abstract] [Full Text] [PDF]

				O. Tredan, C. M. Galmarini, K. Patel, and I. F. Tannock Drug Resistance and the Solid Tumor Microenvironment J Natl Cancer Inst, October 3, 2007; 99(19): 1441 - 1454. [Abstract] [Full Text] [PDF]

				P. Sonveaux, I. I. Lobysheva, O. Feron, and T. J. McMahon Transport and Peripheral Bioactivities of Nitrogen Oxides Carried by Red Blood Cell Hemoglobin: Role in Oxygen Delivery Physiology, April 1, 2007; 22(2): 97 - 112. [Abstract] [Full Text] [PDF]

				M. W. Dewhirst, I. C. Navia, D. M. Brizel, C. Willett, and T. W. Secomb Multiple Etiologies of Tumor Hypoxia Require Multifaceted Solutions Clin. Cancer Res., January 15, 2007; 13(2): 375 - 377. [Full Text] [PDF]

				P. Martinive, J. De Wever, C. Bouzin, C. Baudelet, P. Sonveaux, V. Gregoire, B. Gallez, and O. Feron Reversal of temporal and spatial heterogeneities in tumor perfusion identifies the tumor vascular tone as a tunable variable to improve drug delivery. Mol. Cancer Ther., June 1, 2006; 5(6): 1620 - 1627. [Abstract] [Full Text] [PDF]

				C. Schwencke, R. C. Braun-Dullaeus, C. Wunderlich, and R. H. Strasser Caveolae and caveolin in transmembrane signaling: Implications for human disease Cardiovasc Res, April 1, 2006; 70(1): 42 - 49. [Abstract] [Full Text] [PDF]

				R. Ansiaux, C. Baudelet, G. O. Cron, J. Segers, C. Dessy, P. Martinive, J. De Wever, J. Verrax, V. Wauthier, N. Beghein, et al. Botulinum Toxin Potentiates Cancer Radiotherapy and Chemotherapy Clin. Cancer Res., February 15, 2006; 12(4): 1276 - 1283. [Abstract] [Full Text] [PDF]